Concord Drugs (BOM:538965) Marketable Securities: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
65 GF Score
Price ₹79.47
GF Value ₹64.55
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Concord Drugs Marketable Securities?

Concord Drugs BOM:538965 -0.25% 65 Marketable Securities is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 65/100 and a GF Value™ of ₹64.55 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Concord Drugs's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0.0 Mil.

Concord Drugs's annual Marketable Securities increased from Mar. 2024 (₹0.3 Mil) to Mar. 2025 (₹1.0 Mil) and increased from Mar. 2025 (₹1.0 Mil) to Mar. 2026 (₹5.1 Mil).

Concord Drugs  (BOM:538965) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Concord Drugs Marketable Securities Related Terms

Concord Drugs Marketable Securities Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Marketable Securities Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.21 0.31 1.05 5.10

Concord Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.17 0.00 5.10 0.00
BOM:538965
65GF Score
Concord Drugs Ltd BOM:538965
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0.0 Mil mean?
Concord Drugs (BOM:538965) has a Marketable Securities of ₹0.0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Concord Drugs and its competitors.
Is Concord Drugs' Marketable Securities too high?
Concord Drugs' current Marketable Securities is ₹0.0 Mil. Overall, Concord Drugs has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Marketable Securities compare to ZTS?
Concord Drugs' Marketable Securities of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Concord Drugs and its competitors. Concord Drugs's current Marketable Securities is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹64.55, compared to a current price of ₹79.47 — trading 23.1% above its estimated fair value. The current Marketable Securities is ₹0.0 Mil. Concord Drugs' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Marketable Securities is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹79.47 is trading 23.1% above its estimated GF Value™ of ₹64.55. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Marketable Securities: ₹0.0 Mil
  • GF Value™: ₹64.55 vs. price of ₹79.47 (23.1% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
65GF Score

Get the complete analysis for BOM:538965

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹79.47
Price
₹64.55
GF Value